Core Viewpoint - The complex injection market is emerging as a new avenue for Chinese pharmaceutical companies to break into international markets, driven by high technical barriers and significant clinical value [1][2]. Group 1: Company Developments - Haizheng Pharmaceutical and Zhejiang Shengzhao Pharmaceutical Technology Co., Ltd. have established a joint venture focused on the development, production, and global commercialization of 11 complex injection products, including generics and modified new drugs [1]. - The chairman of Haizheng Pharmaceutical emphasized that complex injections are a key area for differentiated development and an important step in the company's internationalization strategy [1][2]. Group 2: Market Potential - According to Frost & Sullivan, the market size for complex injections in China is projected to reach 40.8 billion yuan by 2025 and 77.9 billion yuan by 2030, with a compound annual growth rate (CAGR) exceeding 13% [1]. - Unlike ordinary generics, complex injections maintain higher price levels due to their technical barriers, providing more growth opportunities for companies [1][2]. Group 3: Challenges in the Industry - The production of complex injections presents significant technical challenges, including high precision in process control and long-term stability verification, with few companies capable of large-scale industrial production [2][3]. - International market entry poses another challenge, as companies must navigate stringent regulatory requirements, particularly in markets like Europe and the U.S. [3]. - The competitive landscape includes companies from Israel, India, and the U.S., necessitating Chinese firms to establish differentiated advantages through technological breakthroughs and large-scale production [3].